NDATOPICALOINTMENT, AUGMENTED
Approved
Jul 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
19
Data completeness
6/8 — Strong
DIPROLENE (betamethasone dipropionate) by Merck & Co. is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of diprolene ointment in corticosteroid responsive dermatoses is unknown. Approved for psoriasis, atopic dermatitis. First approved in 1983.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIPROLENE is an augmented topical ointment formulation of betamethasone dipropionate, a potent corticosteroid approved in 1983 for treating inflammatory dermatological conditions including psoriasis, atopic dermatitis, and chronic rhinosinusitis. The drug works through signaling, immune function modulation, inflammation reduction, and protein regulation, though its precise mechanism in corticosteroid-responsive dermatoses remains incompletely understood.
$0.012BPart D
LOE ApproachingDeclining
As a mature product approaching loss of exclusivity with modest Part D spending ($12K) and low claim volume (53), the brand team is likely focused on defensive strategies and cost management rather than growth initiatives.
Mechanism of Action
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of DIPROLENE Ointment in corticosteroid responsive dermatoses is unknown.
Indications (2)
Clinical Trials (19)
The Effect of Intra-sinus Application of Betamethasone Dipropionate Nasal Cream on Patients with Chronic Rhinosinusitis Post Functional Endoscopic Sinus Surgery (FESS)
Started Aug 2023
24 enrolled
Chronic Rhinosinusitis (Diagnosis)
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
Started Jun 2023
291 enrolled
Plaque Psoriasis
Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream
Started Feb 2022
2 enrolled
Chronic Rhinosinusitis (Diagnosis)
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.
Started Apr 2019
15 enrolled
Psoriasis Vulgaris
Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects
Started Jan 2018
20 enrolled
Psoriasis Vulgaris
Worked on DIPROLENE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.